Scivita Medical Technology has expanded its strategic collaboration with Boston Scientific through a cooperation arrangement for endoscopic devices.
Under the arrangement, the two companies will focus on the co-development of future endoscopic devices and explore global distribution opportunities.
Go deeper with GlobalData
These activities are related to Scivita Medical’s single-use endoscope and imaging devices.
The expanded arrangement is anticipated to facilitate the availability of Scivita Medical’s products to more hospitals and patients in China and other geographies globally.
Boston Scientific Endoscopy senior vice-president and president Mike Jones said: “We are excited to further our relationship with Scivita Medical which we anticipate will help provide physicians with more device options in geographies around the world.
See Also:
“We look forward to successfully building on that relationship with this new arrangement.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataScivita Medical is engaged in the research, development as well as commercialisation of medical endoscopes and related products.
Scivita Medical co-founder, general manager and chief technology officer Dr Chin said: “This strengthened relationship will help us combine our core strengths and expertise to deliver high-quality single-use endoscope solutions to doctors and patients in various regions across the globe.
“Working with a company like Boston Scientific is crucial to Scivita Medical’s globalisation strategy.”
Last year, Scivita Medical signed an agreement with Boston Scientific for its single-use percutaneous choledochoscope.
At that time, Scivita Medical said the collaboration would further broaden the market penetration of its choledochoscope.
Recently, the US Food and Drug Administration (FDA) approved the Agent drug-coated balloon, which is developed by Boston Scientific, for the treatment of coronary in-stent restenosis (ISR), obstruction or narrowing of a stented vessel.
The Agent balloon can inflate to reopen the stent and diffuse paclitaxel – a chemotherapy drug that maintains the patency of the lumen of the blood vessel.
